Aproxi EZY 125 mg+80 mg+80 mg
৳ 350
Side Effects
Pregnancy & Lactation
Use in Special Populations
Patients with Hepatic Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. There are no clinical data in patients with severe hepatic impairment.
Overdose Effects
Therapeutic Class
Storage Conditions
Buy 15 products and get ৳ 20 discount
Description
Indications
- Prevention of postoperative nausea and vomiting (PONV)
- Prevention of Chemotherapy induced nausea and vomiting (CINV)
-
Composition
Aproxi EZY marks a major milestone for Beacon Pharmaceuticals PLC, being the first-ever combi-pack in Bangladesh to offer one 125 mg capsule and two 80 mg capsules conveniently in a single strip- making chemotherapy treatment simpler and easier for patients.Aproxi EZY is designed with one goal: to make life easier for patients undergoing chemotherapy.
Pharmacology
Aprepitant is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors. When substance P attaches to these receptors, it causes nausea and vomiting. Aprepitant stops substance P from binding to the NK1 receptors. By blocking the receptors, Aprepitant can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery.Dosage & Administration
Post Operative Nausea and Vomiting: The recommended oral dosage of Aprepitant is 40 mg within 3 hours prior to induction of anesthesia.Chemotherapy-Induced Nausea and Vomiting: The following regimen should be used for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy-
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg 30 minutes before the start of chemotherapy.
- Day 2: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 3: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 4: Dexamethasone 8 mg orally
Aprepitant is administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3. Dexamethasone is administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The dose of dexamethasone accounts for drug interactions.
The following regimen should be used for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg tablet 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later.
- Day 2: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
- Day 3: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day.
Aprepitant is administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3. Dexamethasone is administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for drug interactions.
Aprepitant may be taken with or without food. No dosage adjustment is necessary for the elderly patients.
Interaction
Aproxi EZY is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4. Aproxi EZY is also an inducer of CYP2C9. Precautions should be taken while coadministering Aproxi EZY with drugs that use CYP3A4 or CYP2C9, for example- Warfarin, Tolbutamide, Phenytoin, Ketoconazole, Itraconazole, Nefazodone, Troleandomycin, Clarithromycin, Ritonavir, Nelfinavir, Diltiazem, Rifampin, Carbamazepine etc.Upon coadministration with Aproxi EZY, the efficacy of hormonal contraceptives during and for 28 days following the last dose of Aproxi EZY may be reduced. Alternative or back-up methods of contraception should be used during treatment with Aproxi EZY and for 1 month following the last dose of Aproxi EZY.
Contraindications
Aprepitant is contraindicated in patients who are hypersensitive to any component of the product. Aprepitant should not be used concurrently with Pimozide, Terfenadine, Astemizole & Cisapride.
Reviews
There are no reviews yet.